An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

Sponsor
Incyte Corporation
Study ID
NCT06910137
Status
Available

Conditions

  • Squamous Cell Carcinoma of the Anal Canal

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • retifanlimab — DRUG
    Administered intravenous as defined in the protocol.

Study Details

To provide retifanlimab, on a reactive basis, to adult patients with squamous carcinoma of the anal canal in combination with carboplatin and paclitaxel and who are considered ineligible for other therapeutic options including clinical trials.

Key Dates

Status verified
Jan 2026

Central Contacts